10:05 - 10:10 amSaturday, September 26
Lower Lobby - West
Does your patient shred the gnar? A new approach to precision medicine, putting the power of science in the hands of patients
Lower Lobby - West
Does your patient shred the gnar? A new approach to precision medicine, putting the power of science in the hands of patients
Founder & Chief Strategy Officer, Cure Forward
The potential of precision medicine is tantalizing.  We see news about technologies, tests, and new therapies every day.  When people receive a cancer diagnosis, however, they are stunned that the power... Read more

Description

The potential of precision medicine is tantalizing.  We see news about technologies, tests, and new therapies every day.  When people receive a cancer diagnosis, however, they are stunned that the power of personalized medicine is just out of reach.  This insight led us to develop a new company, Cure Forward, a website that helps patients play a more active role in care planning through effective access to, and use of, their molecular profiling test data.  We envision a future where patients will be able to work with their doctor to find a test, receive their test results electronically, and put them to purposeful use, including finding trials trials through a multi-sided marketplace.  In this talk, we will describe the Cure Forward product and the story and philosophy behind it.  At this three-month inflection point, we’ll also describe what is happening in this new community.  We’ll share data and insights on participation by patients and clinical trial recruiters, and we’ll candidly assess the success and prospects of the program.  Most of all, we’ll assess whether mobilization of individual consumers is an effective catalyst for widespread adoption of genomics in cancer care and increased patient participation in clinical research.

Martin Naley founded Cure Forward to solve critical needs in patient care and drug development. Patients had heard of precision medicine but didn’t know how to access tests or targeted therapies. Clinical trials were struggling to find patients. The opportunity became apparent for patients to engage in precision medicine and use their own data to find relevant and specific treatments. Martin incubated the idea at Apple Tree Partners, a healthcare venture capital firm, and the company was formed in 2014. Now the Cure Forward website is launched, helping hundreds of patients who are seeking options in their cancer care. Earlier in his career, Martin spent 15 years at Life Technologies, a manufacturer of the tools that power precision medicine.  There, he held various leadership positions including CEO Chief of Staff, Head of Medical Science Informatics, and VP Cell Culture Research. Martin holds a B.A. in Biological Sciences from Cornell and an M.B.A. from Yale.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search